BioLine RX Ltd
TASE:BLRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Mainz Biomed NV
NASDAQ:QUCY
|
DE |
BioLine RX Ltd
Research & Development
BioLine RX Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Research & Development
-$7.5m
|
CAGR 3-Years
27%
|
CAGR 5-Years
19%
|
CAGR 10-Years
5%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Research & Development
-$12.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Research & Development
-$9.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Research & Development
-$67.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Research & Development
-$5.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Research & Development
-$15.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
BioLine RX Ltd
Glance View
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
See Also
What is BioLine RX Ltd's Research & Development?
Research & Development
-7.5m
USD
Based on the financial report for Sep 30, 2025, BioLine RX Ltd's Research & Development amounts to -7.5m USD.
What is BioLine RX Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
5%
Over the last year, the Research & Development growth was 27%. The average annual Research & Development growth rates for BioLine RX Ltd have been 27% over the past three years , 19% over the past five years , and 5% over the past ten years .
